Prior to joining Spero Therapeutics in 2017, she led Investor Relations at Forward Pharma A/S, a development stage company focused on multiple sclerosis. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for … For financial reporting, their fiscal year ends on December 31st. About Spero Therapeutics Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and … Data Provided by Refinitiv. ... Investor Relations… The Investor Relations website contains information about Spero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of […] Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants. In addition to serving as a liaison to the investor community, she provides input on financial strategy […] Sath Shukla is Chief Financial Officer at Spero Therapeutics. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in … Spero Investor and Media Contact: Sharon Klahre Senior Director, Investor Relations 857-242-1547 IR@sperotherapeutics.com. Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. To access the call, please dial (877) 705-6003 (domestic) or (201) 493-6725 (international) and refer to conference ID 13716494. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Minimum 15 minutes delayed. Investor Relations; Institutional Ownership and Shareholders . About Spero TherapeuticsSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Tebipenem HBr advancing towards NDA submission in the second half of 2021. Sharon Klahre – Vice President of Investor Relations … Spero Investor and Media Contact: Sharon Klahre Vice President, Investor Relations 857-242-1547 IR@sperotherapeutics.com Spero Therapeutics, Inc. Condensed Consolidated Statements of … Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. SPRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm The archived webcast will also be available on Spero’s website for 30 days following the call. Learn first-hand where Spero Therapeutics is receiving exposure via self-authored articles or other coverage in the biotech trade media, the business press and in the blogosphere. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Sharon Klahre-- Senior Director of Investor Relations… Spero Investor and Media Contact:Sharon KlahreVice President, Investor Relations857-242-1547IR@sperotherapeutics.com, Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021, ©2021 Spero Therapeutics All Rights Reserved, Tebipenem HBr: Oral Gram-Negative Program. Webcasts of corporate presentations may be accessed through Spero Therapeutics' website (www.sperotherapeutics.com) on the "Events and Presentations" page under the "Investors … Spero Therapeutics, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Source: Spero Therapeutics, Inc. For more information, visit https://sperotherapeutics.com. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Please go ahead, ma'am. CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline. Sharon Klahre is the Vice President of Investor Relations and Strategic Finance at Spero Therapeutics. Webcasts of the presentations may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors … Spero Therapeutics is looking for a collaborative, enthusiastic leader responsible for the strategic and operational leadership of all investor relations and corporate communications activities for Spero Therapeutics. ©2021 Spero Therapeutics All Rights Reserved, Oppenheimer Healthcare Conference – March 16, 2021, Tebipenem HBr: Oral Gram-Negative Program. Spero Investor and Media Contact: Sharon Klahre Vice President, Investor Relations 857-242-1547 IR@sperotherapeutics.com Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securiti Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Spero Therapeutics, Inc. ... Vice President of Investor Relations and Strategic Finance. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. The Investor Relations website contains information about Spero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. These institutions hold a total of 21,358,106 shares. Sharon Klahre is Director, Investor Relations at Spero Therapeutics, Inc. View Sharon Klahre’s professional profile on Relationship Science, the database of decision makers. Earlier today, Spero Therapeutics released financial results and provided a pipeline update for the third quarter ended September 30, 2020. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Securities registered pursuant to Section 12(g) of the Act: None . Conference call and live webcast at 4:30 p.m. EST today. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Mr. Sharon Klahre – Senior Director-Investor Relations. Spero Therapeutics, Inc is primarely in the business of pharmaceutical preparations. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. ... Vice President, Investor Relations 857-242-1547 CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive … February 24, 2021 – Timmerman Report Comprehensive Policy for Infection: There Has Never Been a Better Time (Blog post authored by Ankit Mahadevia) Spero Therapeutics Inc (US:SPRO) has 202 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). ... Vice President, Investor Relations 857-242-1547 He was most recently Chief Financial Officer at Ziopharm Oncology, Inc., where he directed all of Ziopharm’s financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. ... Vice President, Investor Relations 857-242-1547 Sharon Klahre is VP:Investor Relations at Spero Therapeutics Inc. See Sharon Klahre's compensation, career history, education, & memberships. Spero Therapeutics, Inc. (SPRO) Q3 2020 Earnings Call Transcript. Sath Shukla is Chief Financial Officer at Spero Therapeutics. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc., where he directed all of Ziopharm’s financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. At this time, I'd like to turn the call over to Sharon Klahre, Vice President of Investor Relations and Strategic Finance. Spero Therapeutics, Inc. (SPRO) Q1 2020 Earnings Call Transcript SPRO earnings call for the period ending March 31, 2020.